![conference banner](/images/conference-banner.jpeg)
Abstract
Microparticles are circulating fragments derived from blebbing and shedding of cell membranes through several mechanisms that include activation, apoptosis and cell damage. In the past they were largely considered as unimportant cell “dust”, but more refined detection techniques have revealed large variations in their relative proportion and concentration in numerous disease states. Importantly, these conditions include the most prevalent causes of death and disability in our societies, namely cardiovascular, neoplastic, and inflammatory diseases. Microparticles carry procoagulant, proapoptotic and neoangiogenetic materials in the blood stream, and can also be viewed as a technique cells may adopt to rapidly modify their phenotype, independently from genetic signals. In this review, we focus on the role of these very small ( < 1 micron) particles, not only as mere markers of an underlying pathologic state, but also as primordial intercellular messengers and defense mechanism that every viable cell can exploit in distress conditions. In this view, we suggest that this old communication system could be the target of future high-tech interventions, with potential broad consequences.
Keywords: Microparticles, atherosclerosis, coagulation, inflammation, apoptosis, angiogenesis, endothelial dysfunction, atrial fibrillation, renal failure, diabetes mellitus
Current Vascular Pharmacology
Title: Microparticles in Health and Disease: Small Mediators, Large Role?
Volume: 9 Issue: 4
Author(s): Italo Porto, Giovanni Luigi De Maria, Luca Di Vito, Claudia Camaioni, Massimo Gustapane and Luigi Marzio Biasucci
Affiliation:
Keywords: Microparticles, atherosclerosis, coagulation, inflammation, apoptosis, angiogenesis, endothelial dysfunction, atrial fibrillation, renal failure, diabetes mellitus
Abstract: Microparticles are circulating fragments derived from blebbing and shedding of cell membranes through several mechanisms that include activation, apoptosis and cell damage. In the past they were largely considered as unimportant cell “dust”, but more refined detection techniques have revealed large variations in their relative proportion and concentration in numerous disease states. Importantly, these conditions include the most prevalent causes of death and disability in our societies, namely cardiovascular, neoplastic, and inflammatory diseases. Microparticles carry procoagulant, proapoptotic and neoangiogenetic materials in the blood stream, and can also be viewed as a technique cells may adopt to rapidly modify their phenotype, independently from genetic signals. In this review, we focus on the role of these very small ( < 1 micron) particles, not only as mere markers of an underlying pathologic state, but also as primordial intercellular messengers and defense mechanism that every viable cell can exploit in distress conditions. In this view, we suggest that this old communication system could be the target of future high-tech interventions, with potential broad consequences.
Export Options
About this article
Cite this article as:
Porto Italo, Luigi De Maria Giovanni, Di Vito Luca, Camaioni Claudia, Gustapane Massimo and Marzio Biasucci Luigi, Microparticles in Health and Disease: Small Mediators, Large Role?, Current Vascular Pharmacology 2011; 9 (4) . https://dx.doi.org/10.2174/157016111796197206
DOI https://dx.doi.org/10.2174/157016111796197206 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bradykinin Receptors in Ischemic Injury
Current Neurovascular Research Pathophysiology of Post-Operative Low Cardiac Output Syndrome
Current Vascular Pharmacology Progress in Imaging Agents of Cell Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Triple Threat: The Na+/Ca2+ Exchanger in the Pathophysiology of Cardiac Arrhythmia, Ischemia and Heart Failure
Current Drug Targets Targeting Drugs to APJ Receptor: The Prospect of Treatment of Hypertension and Other Cardiovascular Diseases
Current Drug Targets New Heterocyclic Compounds: Synthesis, Antioxidant Activity and Computational Insights of Nano-Antioxidant as Ascorbate Peroxidase Inhibitor by Various Cyclodextrins as Drug Delivery Systems
Current Drug Delivery Flavonoids in the Treatment of Diabetes: Clinical Outcomes and Mechanism to Ameliorate Blood Glucose Levels
Current Diabetes Reviews Refining the Indications of Implantable Cardioverter Defibrillator in Patients with Left Ventricular Dysfunction
Reviews on Recent Clinical Trials Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-of-the-Art Review
Cardiovascular & Hematological Agents in Medicinal Chemistry Sexual Dysfunction in Men and Women with Diabetes: A Reflection of their Complications?
Current Diabetes Reviews Ivabradine: A Current Overview
Current Clinical Pharmacology Mitochondrial Biogenesis: Regulation By Endogenous Gases During Inflammation and Organ Stress
Current Pharmaceutical Design Pentraxins: CRP and PTX3 and Cardiovascular Disease
Inflammation & Allergy - Drug Targets (Discontinued) Therapeutic Targets for Heart Failure: Beyond Beta-Adrenergic and Renin-Angiotensin System Blockade
Recent Patents on Cardiovascular Drug Discovery Pathogenesis of the Left Ventricular Diastolic Dysfunction: The Immune System Keeps Playing at the Backstage
Endocrine, Metabolic & Immune Disorders - Drug Targets Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases
Current Pharmaceutical Design Targeting the Fatty Acid Transport Proteins (FATP) to Understand the Mechanisms Linking Fatty Acid Transport to Metabolism
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Mutation p.S335X in GATA4 Reduces its DNA Binding Affinity and Enhances Cell Apoptosis Associated with Ventricular Septal Defect
Current Molecular Medicine Antithrombotic Treatment in Cardiomyopathies
Current Pharmaceutical Design Editorial [Hot topic: Crucial Role of Redox Signaling in the Regulation of Heart Health (Guest Editor: Dipak K. Das)]
Current Cardiology Reviews